Kumaresh
Kumaresh Gettamaneni, Wellington, CO US
Patent application number | Description | Published |
---|---|---|
20140102544 | HIGH-TEMPERATURE THERMAL ACTUATOR UTILIZING PHASE CHANGE MATERIAL - Disclosed is a high-temperature thermal actuator that utilizes the dimensional change of a phase change media hermetically sealed within a shell. This actuator regulates and controls flow of a fluid between an intake and an exhaust utilizing a valve. In one example, the disclosed embodiments operate in temperature range between 350° C. and 400° C. This actuation range is tailored for specific applications utilizing an exemplary combination of RbNO | 04-17-2014 |
Kumaresh Govindan Radhakrishnan, Singapore SG
Patent application number | Description | Published |
---|---|---|
20120145770 | APPARATUS FOR INCREASING COVERAGE OF SHIELDING GAS DURING WIRE BONDING - A main body of an apparatus for delivering shielding gas during wire bonding of an electronic device has a through-hole in the main body which is sized for allowing a capillary tip of a bonding tool to be insertable through the main body when performing wire bonding. At least one gas outlet located on a bottom surface of the main body adjacent to the through-hole is operative to direct an inert gas in a direction towards the electronic device. At least one gas inlet in the main body is operative to supply the inert gas to the through-hole and to the gas outlet. | 06-14-2012 |
20140348624 | TRANSFER DEVICE FOR HOLDING AN OBJECT USING A GAS FLOW - Disclosed is a transfer device for holding an object. The transfer device comprises: i) a housing having a housing surface; ii) at least one inlet conduit having an inlet for introducing a gas into the at least one inlet conduit; iii) a plurality of sets of outlet conduits, each set of outlet conduits being in fluid communication with the at least one inlet conduit and having a plurality of outlets for directing the gas out of the outlet conduits. In particular, the respective outlets of the sets of outlet conduits are arranged in a direction along the housing surface and away from a centre region relative to the respective sets of outlet conduits, so that a laminar gas flow that is flows along the housing surface generates a pressure differential which creates a force towards the centre region to hold the object against the housing surface. A gang picker is also disclosed. | 11-27-2014 |
Kumaresh Soppimath, Claremont, CA US
Patent application number | Description | Published |
---|---|---|
20100143481 | METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described. | 06-10-2010 |
Kumaresh Soppimath, Monmouth Jn, NJ US
Patent application number | Description | Published |
---|---|---|
20140080880 | Bendamustine Formulations - A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.5 wt % by weight of impurities is administered to the subject in need thereof. | 03-20-2014 |
20140303254 | Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation - A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient is provided. The oxidation susceptible active pharmaceutical ingredient is mixed with excipients and deoxygenated water to prepare a non-sterile drug solution. The non-sterile drug solution is filled into a moist heat sterilizable flexible infusion bag. The flexible infusion bag with the non-sterile drug solution is terminally moist heat sterilized at a preset air overpressure between about 0.2 bar to about 1.2 bar to obtain a parenteral drug product. The highest degradation product in the parenteral drug product is less than 0.5% by weight of a labeled amount of the oxidation susceptible active pharmaceutical ingredient in the parenteral drug product. | 10-09-2014 |
Kumaresh Soppimath, Monmouth Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20130210878 | BENDAMUSTINE COMPOSITIONS AND METHODS THEREFORE - Aqueous Bendamustine formulations with improved stability are disclosed. Especially preferred formulations are low-dose ready-to-use liquid formulations in which Bendamustine is in a non-aqueous vehicle in combination with an aqueous phase that contains significant quantities of chloride. | 08-15-2013 |
20130310397 | TERNARY MIXTURE FORMULATIONS - The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly- water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution. | 11-21-2013 |
20130317016 | Aprepitant Injectable Formulations - An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time. | 11-28-2013 |
Kumaresh Soppimath, Monmouth, NJ US
Patent application number | Description | Published |
---|---|---|
20110230441 | STABLE BORTEZOMIB FORMULATIONS - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 09-22-2011 |
20120172808 | Stable Bortezomib Formulations - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 07-05-2012 |
20120322762 | Stable Bortezomib Formulations - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 12-20-2012 |
20120322763 | Stable Bortezomib Formulations - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 12-20-2012 |
Kumaresh Soppinath, Monmouth, NJ US
Patent application number | Description | Published |
---|---|---|
20140073583 | STABLE COMPOSITIONS OF PEPTIDE EPOXY KETONES - The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib. | 03-13-2014 |